Studies have shown that PPAR-γ can modulate drug resistance in cancer cells, including gastric cancer, and when it is either downregulated or suppressed, this can lead to an increase in the survival of cancer cells even in the presence of PTX [22]. Here, PPARG is linked to cancer.